Indiana Administrative Code
Title 845 - BOARD OF PODIATRIC MEDICINE
Article 2 - OPIOID PRESCRIBING REQUIREMENTS
Rule 1 - General Provisions
Section 1-5 - Podiatrist discussion with patient; treatment agreement
Current through March 20, 2024
Authority: IC 25-22.5-13-3
Affected: IC 25-1-9; IC 25-29
Sec. 5.
The podiatrist shall discuss with the patient the potential risks and benefits of opioid treatment for chronic pain, as well as expectations related to prescription requests and proper medication use. In doing so, the podiatrist shall:
(1) Where alternative modalities to opioids for managing pain exist for a patient, discuss them with the patient.
(2) Provide a simple and clear explanation to help patients understand the key elements of their treatment plan.
(3) Counsel women between fourteen (14) and fifty-five (55) years of age with child bearing potential about the risks to the fetus when the mother has been taking opioids while pregnant. Such described risks shall include fetal opioid dependency and neonatal abstinence syndrome (NAS).
(4) Discuss with the patient risks of dependency and addiction.
(5) Discuss with the patient safe storage practices for prescribed opioids.
(6) Provide a written warning to the patient disclosing the risks associated with taking extended release medications that are not in an abuse deterrent form, if the podiatrist prescribes for the patient a hydrocodone-only extended release medication that is not in an abuse deterrent form.
(7) Discuss with the patient the risks and benefits of using an abuse deterrent formulation, as opposed to a non-abuse deterrent formulation, if such a formulation exists for the opioid product the podiatrist is prescribing to the patient.
(8) Together with the patient, review and sign a "Treatment Agreement", which shall include at least the following: